AstraZeneca

Capivasertib (Truqap) combined with abiraterone acetate (Zytiga) and androgen deprivation therapy (ADT) significantly improved radiographic progression-free survival (rPFS) in PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC) patients, according to the phase 3 CAPItello-281 trial. The safety profile remained consistent with known profiles of each agent, and while overall survival (OS) data were immature, a trend favored the capivasertib regimen. Results will be presented at a future medical conference.

Daiichi Sankyo plans to build a $152 million facility in Shanghai to produce antibody-drug conjugates for cancer treatments in response to growing Chinese demand.

A study in The Lancet Respiratory Medicine suggests benralizumab, an injection, may be a breakthrough treatment for asthma and COPD flare-ups, reducing treatment failure rates and side-effects compared to steroids like prednisolone.

Roche to acquire Poseida Therapeutics for $1 billion. Merck, AstraZeneca, and Novartis see success in new drug studies. Novartis' Kisqali approved for broader breast cancer treatment in EU.

The article discusses the importance of enabling JavaScript for optimal app performance.

A UK study found benralizumab, currently used for severe asthma, could be a new treatment for asthma attacks, outperforming standard steroid tablets. The ABRA phase 2 trial, led by King’s College London and the University of Oxford, showed benralizumab improved respiratory symptoms and reduced treatment failure rates. The drug, already approved for severe eosinophilic asthma, targets eosinophils and could reduce doctor/hospital visits. A phase 3 trial is planned for 2025.

Kelun-Biotech's sacituzumab tirumotecan (sac-TMT) receives NMPA approval in China for triple-negative breast cancer, competing with Gilead's Trodelvy. The drug, also under review for EGFR-mutant NSCLC, is partnered with MSD, potentially worth up to $1.4 billion. Phase 3 study results showed a 47% reduction in death risk.

Qiagen announces new site in Barcelona for QIAstat-Dx operations, expanding its capabilities for respiratory, gastrointestinal, and meningitis/encephalitis testing. The facility, set to open in 2026, will include manufacturing, R&D, sales, marketing, quality assurance, and regulatory affairs teams, and is designed to meet LEED Platinum Certification standards.

HUTCHMED announces renewal of ORPATHYS® (savolitinib) inclusion in China's National Reimbursement Drug List (NRDL) effective January 1, 2025, maintaining current terms. ORPATHYS®, an oral MET TKI, received conditional approval in China in 2021 for treating NSCLC with MET exon 14 skipping alterations. The NRDL inclusion aims to improve drug affordability, covering 95% of China's population.